They have developed precision drugs and diagnostic devices that target the tumor stroma, including Antibody-Drug Conjugates (ADCs) and human-derived proteins. These target peritumoral fibroblasts, endothelial cells, and extracellular matrix that promote tumor invasiveness, drug resistance, and immunosuppression. Oncomatryx's ADCs have unique payloads and linker derivatives that effectively treat pancreatic cancer in vivo. Their ADC, OMTX705, inhibits pancreatic tumor growth in mice, both alone and in combination with chemotherapy.